Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.34 USD

1.34
2,474,352

+0.01 (0.75%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AKBA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Akebia Therapeutics, Inc. [AKBA]

Reports for Purchase

Showing records 1 - 20 ( 81 total )

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

03/28/2024

Company Report

Pages: 6

FDA Approves Vafseo For Anemia in CKD on Dialysis; Akebia to Launch Vafseo in January 2025; Raise PT to $6.00

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

03/15/2024

Company Report

Pages: 8

4Q Recap; We Anticipate Vadadustat''s U.S. Approval By March 27 PDUFA Date

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

01/31/2024

Company Report

Pages: 5

Balance Sheet Strengthened Within Just Two Months of Potential FDA Approval of Vadadustat; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

11/17/2023

Company Report

Pages: 8

3Q Recap; Expecting Vadadustat''s U.S. Approval By March 27, 2024; Increasing PT to $5 on New Estimated Pricing

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

10/25/2023

Daily Note

Pages: 3

Vadadustat NDA Resubmission Formally Accepted; We Expect Approval by March 27, 2024, PDUFA Date; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

09/28/2023

Daily Note

Pages: 3

Akebia Resubmits Vadadustat NDA; We Expect FDA Approval Near the End of March 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

09/27/2023

Company Report

Pages: 7

Vadadustat Now Approved in Australia; NDA Resubmission For U.S. Approval Remains on Target by End of 3Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

08/28/2023

Company Report

Pages: 7

FDA Meeting Minutes Confirm Regulatory Path; We Now Anticipate Vadadustat Approval in March 2024; Upgrade to Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

08/11/2023

Daily Note

Pages: 3

Delayed 10-Q Filing Should Not Impact 2023 Auryxia Sales Guidance, Vadadustat NDA Resubmission or Cash Runway

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

06/21/2023

Daily Note

Pages: 3

Vafseo''s European Market Opportunity Expands With Swissmedic Approval; Maintain Neutral Ahead of FDA Type A Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

06/14/2023

Daily Note

Pages: 3

Akebia Appoints New CFO; Awaiting Type A Meeting Minutes to Confirm Vadadustat''s U.S. Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

06/02/2023

Daily Note

Pages: 3

Last Settlement Reached for Generic Auryxia ANDA; Next Catalyst is Vadadustat FDA Type A Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

05/30/2023

Daily Note

Pages: 4

FDA Offers a Straightforward Path for Vadadustat; Akebia to Resubmit NDA in 2H23, Rekindling Hopes of FDA Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

05/26/2023

Company Report

Pages: 8

Vafseo''s Launch in Europe Licensed to Experienced Partner; FDRR Response Remains Key Catalyst; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

05/22/2023

Daily Note

Pages: 3

MHRA Approval Adds Another Feather to Vafseo''s Cap For Partnership Discussions; Maintain Neutral Ahead of FDRR Response

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

05/09/2023

Company Report

Pages: 8

1Q Recap; FDRR Response Expected Within 30 Days to Determine Vadadustat''s U.S. Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

04/26/2023

Company Report

Pages: 8

Vafseo Approved in EU As Anticipated; We Expect Partnership Talks to Accelerate; Increasing PT to $2; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

03/31/2023

Daily Note

Pages: 3

Latest Dialog With OND on Vadadustat FDRR Was Productive; Response Expected in 2Q23; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

03/10/2023

Company Report

Pages: 6

4Q Recap; Vadadustat Approaches Multiple Regulatory Decisions; We Expect FDRR Outcome in Mid-2023; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

02/24/2023

Daily Note

Pages: 3

Positive CHMP Opinion For Vafseo in Europe; We Anticipate a Commercial Partnership Post-Approval; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party